Navigation Links
Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
Date:5/28/2008

on-small cell lung cancer

in 2009.

New Targets Initiative to Feed Early-Stage Pipeline

HGS has a rich heritage of scientific discovery that has produced a vast intellectual property estate and a library of thousands of therapeutic and diagnostic targets. Over the past couple of years, HGS has conducted a careful review and selected approximately 50 targets for further research and potential development, with the goal of filing new IND's in 2010-2011.

HGS plans to develop the selected targets through co-development or research collaborations, as well as through its own internal research, including the application of antibody development technology from collaborators such as Cambridge Antibody Technologies and Xencor.

DARAPLADIB ADVANCING TO PHASE 3 TRIALS FOR THE TREATMENT OF ATHEROSCLEROSIS

Darapladib, a small-molecule inhibitor of Lp-PLA2, was discovered by GSK based on HGS technology. HGS will receive a 10% royalty on worldwide sales of darapladib if it is commercialized, and also has a 20% co-promotion option in North America and Europe.

In April 2008, GSK announced that it intends to advance darapladib to Phase 3 clinical trials as a potential treatment for atherosclerosis and will shortly start discussions with regulators regarding the structure of the darapladib Phase 3 program. Darapladib has the potential to be an important treatment for atherosclerosis.

At the American College of Cardiology's 57th Annual Scientific Session in March, GSK presented data from a randomized Phase 2 dose-ranging trial of darapladib in patients with coronary heart disease (CHD). The study showed that darapladib produced sustained, dose-dependent inhibition of plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in patients receiving intensive atorvastatin (cholesterol-lowering) therapy. Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques and identified in clinical trials as an independ
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
2. St. Jude Finds Dancing Hair Cells Are Key to Humans Acute Hearing
3. Increases in West Nile Virus Replikin Concentrations Precede Increases in the Number of Human Cases
4. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
5. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
6. First Human Implant of New Archus Orthopedics Facet Replacement System
7. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
8. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
9. Data Show SuperGens MP-470 is Safe in Humans
10. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
11. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... MASON, Ohio , Dec. 23, 2014 /PRNewswire/ ... industry-leading treatment decision support to healthcare providers for ... that it has secured $30 million in equity ... Virginia C. Drosos , President and Chief ... increased clinical adoption and development of Assurex Health,s ...
(Date:12/24/2014)... Va. , Dec. 23, 2014  The ... diastolic blood pressure target for people with diabetes ... moderate or high doses of statins, in keeping ... management enacted by the American College of Cardiology ... are reflected in the most recent changes to ...
(Date:12/24/2014)... , Dec. 23, 2014 In response to urgent ... of Sierra Leone , Direct Relief delivered ... for the treatment of local health workers who contract ... new dedicated Ebola care center was constructed for foreign health ... is not available for local Sierra Leonean health workers. ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced ... Citi 2011 Global Health Care Conference on Thursday, ... Hilton New York Hotel in New York City. Cowen ... 7, 2011 at 4:45 p.m. Eastern Time at The Boston ...
... March 1, 2011 / PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) ... biotechnology and medical device R&D outsourcing company with operations ... it will release financial results for the fourth quarter ... on Tuesday, March 8, 2011 (which will be Wednesday ...
Cached Medicine Technology:Optimer Pharmaceuticals to Present at March 2011 Investor Conferences 2WuXi PharmaTech Schedules Fourth-Quarter 2010 Earnings Release 2
(Date:12/25/2014)... (PRWEB) December 26, 2014 The report ... 2023” focuses on the current treatment landscape, unmet needs, ... market. TS-1 is an anti-cancer drug which is typically ... and is also used for treating gastric cancer and ... otastat potassium. The drug was first approved in 1999 ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The short film ... was created in honor of a true 9/11 hero, Welles ... film festivals including the 24 hours of Nuremberg International Short ... Bangladesh. , Actress, screenwriter and director Luciana Lagana ... this film together with her husband, Gregory Graham ...
(Date:12/25/2014)... December 25, 2014 Recently, LunaDress.co.uk has updated its ... and related accessories. Now, all of the models at LunaDress.co.uk come ... a groom lifts the wedding veil can turn out to be ... charm. A wedding veil can always bring surprise to a wedding. ... on how to choose veils for a big day . ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 (HealthDay ... of youth" drug that can delay the effects of aging ... suggests. Seniors received a significant boost to their immune ... pathway linked to aging and immune function, researchers with the ... a version of the drug rapamycin, improved the seniors, immune ...
(Date:12/25/2014)... 2014 Residents at Abernethy ... showed their generous spirit by providing holiday gifts ... Parenting Network- Grandparents Raising Grandchildren program. , Following ... the largest Christmas tree on the campus of ... residents of the Abernethy Village Association (AVA). Each ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2
... Health Organization (WHO) figures show that each year an ... in the world. The growth of this disease remains ... of HIV patients (nearly 13% compared with less than ... the world is experiencing accelerating advance of a deadly ...
... Dog On It! Fortified Juice Beverages for Kids Pledges up to ... $650,000 for Type 1 Diabetes Research, ... Dog On,It! fortified juice beverage for kids, announced today the launch ... the world,s leading charitable funder of type 1,diabetes research., As ...
... RICHMOND, Calif., March 5 Transcept,Pharmaceuticals, Inc. today ... Chief Financial Officer, will present at Cowen and ... Marriott Copley Place on,Thursday, March 20, 2008 at ... Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical ...
... On Saturday, March,29 at 8:00 am, the Bowen ... Waters Park in Annapolis to raise money to fight ... experience a beautiful 5K,waterfront course complete with activities for ... proceeds from the event go toward the Bowen,Foundation, an ...
... for oil exploration now researchers at The University ... steroid test using hydropyrolysis. , The process which ... and make-up of a sample has been refined ... tests for detecting levels of illicit steroids in urine. ...
... Corporation,(ADAMS), the leading provider of program management and ... of Deborah (Debbie) J.,Aiken and Brandon L. Cannaday ... have joined ADAMS as Associate Project Managers within ... both based out of ADAMS,Cleveland, Ohio office location ...
Cached Medicine News:Health News:A new more effective tuberculosis screening test for HIV victims 2Health News:A new more effective tuberculosis screening test for HIV victims 3Health News:White Hat Brands, Juvenile Diabetes Research Foundation Offer the 'Juice' on New Partnership 2Health News:White Hat Brands, Juvenile Diabetes Research Foundation Offer the 'Juice' on New Partnership 3Health News:Inaugural Bowen Foundation Run/Walk to Fight Autism in Maryland Set for Saturday, March 29 2Health News:New steroid test uses oil exploration technique 2Health News:ADAMS Welcomes Debbie Aiken and Brandon Cannaday to the Firm's Staff as Associate Project Managers 2Health News:ADAMS Welcomes Debbie Aiken and Brandon Cannaday to the Firm's Staff as Associate Project Managers 3
... Cardiology specific EMR / PM system ... nationwide,enabling more effective patient care decisions.,AcerMed's ... clinicians with critical information on a ... care.,Our Cardiology specific clinical pathways have ...
...
... is estimated that 25% of women and 15% ... United States, more than half of adults over ... unsightly venous disease., The VenaCure Laser Vein Treatment ... the treatment of varicose veins. VenaCure offers your ...
ELVeS is a new minimally-invasive laser treatment for patients with superficial vein reflux of the greater saphenous vein. The ELVeS laser treatment offers your patients an effective out-patient alt...
Medicine Products: